# US 2017/0283851 A1 · Resonance Energy Transfer Assay with Cleavage Sequence and Spacer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283851 A1
- Document ID: US20170283851A1
- Status: Published application
- Kind: A1
- Application number: 15/620,062
- Filed: 2017-06-12
- Published: 2017-10-05
- Earliest claimed: 2007-09-14
- Assignees: BioMadison, Inc.
- Applicants: Biomadison, Inc.
- Inventors: Robert D. FISH; Min Dong
- Web page: https://patentgrep.com/patent/US20170283851A1

## CPC

- C12Q 1/37: involving peptidase or proteinase
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/47: from mammals
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/9406: {Neurotransmitters}
- C07K 2319/50: containing protease site
- C07K 2319/60: containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
- G01N 2021/6432: {Quenching}
- G01N 2333/952: derived from bacteria
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for the identification of inhibitors of botulinum neurotoxins are described. Cells are provided that are genetically engineered to express peptides that act as a substrate for a botulinum neurotoxin and the provide reporting groups. Spacer sequences between the reporting groups serve to optimize energy transfer between the reporting groups. Characterization of the energy transfer-dependent signal prior to and following exposure to a botulinum neurotoxin in the presence of a candidate inhibitor provides a measure of the effectiveness of the candidate inhibitor.

## Claims

### Claim 1

A method of screening for an inhibitor of a botulinum neurotoxin, comprising:
providing a cell genetically engineered to express a construct comprising donor label and an acceptor label positioned to provide an electronic coupling such that the donor can transfer energy to the acceptor by a dipole-dipole coupling mechanism, and
a linker disposed between the donor label and the acceptor label, wherein the linker is a peptide sequence comprising (a) a cleavage site peptide comprising a SNARE motif, (b) a first peptide spacer interposed between the donor and the cleavage site peptide, and (c) a second peptide spacer interposed between the acceptor and the cleavage site peptide, wherein the first peptide spacer and the second peptide spacer each comprise three to fifteen amino acids and are selected to both increase the primary structure distance between the donor and the acceptor and reduce the tertiary structure distance between the donor and the acceptor relative to a corresponding construct lacking the first spacer and second spacer, such that the construct is characterized by increased electronic coupling between the donor and the acceptor relative to a corresponding construct lacking the first spacer and second spacer;
characterizing a first signal from the cell;
contacting the cell with a botulinum neurotoxin in the presence of a candidate inhibitor; and
following contacting the cell with the botulinum neurotoxin, characterizing a second signal from the cell.

### Claim 2 (depends on 1)

The method of claim 1, comprising the step of identifying the candidate inhibitor as an effective inhibitor of the botulinum neurotoxin when comparison of the second signal to the first signal is indicative of a lack of decrease in the electronic coupling.

### Claim 3 (depends on 1)

The method of claim 1, wherein the candidate compound is a member of a library of compounds.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method is a high throughput method.

### Claim 5 (depends on 1)

The method of claim 1, wherein at least one of the donor and the acceptor is at least one of a fluorophore and a chromophore.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dipole-dipole coupling mechanism is a Förster resonance energy transfer (FRET).

### Claim 7 (depends on 1)

The method of claim 1, wherein the linker has a primary structure length ≧5 nm.

### Claim 8 (depends on 1)

The method of claim 1, wherein the linker has a primary structure length ≧8 nm.

### Claim 9 (depends on 1)

The method of claim 1, wherein the linker has a primary structure length ≧12 nm.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cleavage site peptide comprises a SNARE protein mutein.

### Claim 11 (depends on 1)

The method of claim 1, wherein the candidate inhibitor comprises an activity related to cellular entry to the cell.

### Claim 12 (depends on 1)

The method of claim 1, wherein the candidate inhibitor comprises an activity related to translocation through a vesicle membrane of the cell.

### Claim 13 (depends on 1)

The method of claim 1, wherein the candidate inhibitor interacts with a receptor of the genetically engineered cell.

### Claim 14

A method of screening for an inhibitor of a botulinum neurotoxin, comprising:
providing a cell genetically engineered to express a construct comprising donor label and an acceptor label positioned to provide an electronic coupling such that the donor can transfer energy to the acceptor by an electronic hop between the donor label and the acceptor label, and
a linker disposed between the donor label and the acceptor label, wherein the linker is a flexible peptide sequence comprising (a) a cleavage site peptide comprising a SNARE motif, (b) a first peptide spacer interposed between the donor and the cleavage site peptide, and (c) a second peptide spacer interposed between the acceptor and the cleavage site peptide, wherein the first peptide spacer and the second peptide spacer each comprise three to fifteen amino acids and are selected to both increase the primary structure distance between the donor and the acceptor and reduce the tertiary structure distance between the donor and the acceptor relative to a corresponding construct lacking the first spacer and second spacer, such that the construct is characterized by an increase in the electronic hop between the donor and the acceptor relative to a corresponding construct lacking the first spacer and second spacer;
characterizing a first signal from the cell;
contacting the cell with a botulinum neurotoxin in the presence of a candidate inhibitor; and
following contacting the cell with the botulinum neurotoxin, characterizing a second signal from the cell.

### Claim 15 (depends on 13)

The method of claim 13, comprising the step of identifying the candidate inhibitor as an effective inhibitor of the botulinum neurotoxin when comparison of the second signal to the first signal is indicative of a lack of decrease in the electronic coupling.

### Claim 16 (depends on 14)

The method of claim 14, wherein the candidate compound is a member of a library of compounds.

### Claim 17 (depends on 14)

The method of claim 14, wherein the method is a high throughput method.

### Claim 18 (depends on 14)

The method of claim 14, wherein at least one of the donor and the acceptor is at least one of a fluorophore and a chromophore.

### Claim 19 (depends on 14)

The method of claim 14, wherein the linker has a primary structure length ≧5 nm.

### Claim 20 (depends on 14)

The method of claim 14, wherein the linker has a primary structure length ≧8 nm.

### Claim 21 (depends on 14)

The method of claim 14, wherein the linker has a primary structure length ≧12 nm.

### Claim 22 (depends on 14)

The method of claim 14, wherein the cleavage site peptide comprises a SNARE protein mutein.

### Claim 23 (depends on 14)

The method of claim 14, wherein the candidate inhibitor comprises an activity related to cellular entry to the cell.

### Claim 24 (depends on 14)

The method of claim 14, wherein the candidate inhibitor comprises an activity related to translocation through a vesicle membrane of the cell.

### Claim 25 (depends on 14)

The method of claim 14, wherein the candidate inhibitor interacts with a receptor of the genetically engineered cell.
